Alector announced two material terminations. GSK delivered notice on Jul. 6, 2026 to end the companies' Collaboration and License Agreement for progranulin-elevating antibodies, with termination effective Jan. 2, 2027, following setbacks in Phase 3 and Phase 2 studies. Separately, on Jul. 8, 2026, Alector repaid $10,428,827.77 of principal and terminated its Loan and Security Agreement with lenders led by Hercules Capital, also covering accrued interest and applicable end-of-term and prepayment charges. The moves wind down the GSK alliance and eliminate outstanding debt, aiming to streamline operations and financial obligations.
Agreement 1: Alector Receives GSK Notice to Terminate Progranulin Collaboration, Effective Jan. 2, 2027
- Agreement terminated: Collaboration and License Agreement for progranulin-elevating antibodies
- Counterparty: GSK
- Original agreement date: Jul 01 2021
- Termination date: Jan 02 2027
- Termination type: Early
- Exit fees / payments: N/A
- Reason: Clinical trial setbacks for latozinemab and nivisnebart
Agreement 2: Alector Repays $10.4 Million and Terminates Hercules Loan Agreement
- Agreement terminated: Loan and Security Agreement
- Counterparty: Hercules Capital
- Original agreement date: Nov 14 2024
- Termination date: Jul 08 2026
- Termination type: Early
- Exit fees / payments: N/A
- Reason: Reduce debt and interest costs; enhance financial flexibility
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.